Literature DB >> 18370086

Differentiation and characterization of human MSCs.

Roxanne L Reger1, Alan H Tucker, Margaret R Wolfe.   

Abstract

One of the hallmark characteristics of human MSCs (hMSCs) is their ability to differentiate into adipocytes, chondrocytes and osteocytes in culture. The default fate for hMSCs appears to be bone: if late-passage cultures are left in basic culture medium, the hMSCs will become confluent and produce mineral, an indication of bone formation. However, when grown under certain culture conditions or in media containing specific components, the cells can be driven to become a number of other specific cell types including neural cells, myocytes, and cardiomyocytes. The protocols given here are the basic differentiation procedures for inducing osteogenesis, adipogenesis, and chondrogenesis in cultures of hMSCs. Although there is still no clear consensus on the antigen expression pattern that will define hMSCs, a protocol is also presented for the flow cytometric analysis using a series of antibody panels. The analysis of these surface epitope patterns can aide in the isolation and characterization of hMSCs.

Entities:  

Mesh:

Year:  2008        PMID: 18370086     DOI: 10.1007/978-1-60327-169-1_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  22 in total

Review 1.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

2.  The isolation and cultivation of bone marrow stem cells and evaluation of differences for neural-like cells differentiation under the induction with neurotrophic factors.

Authors:  Jian-Dong Yang; Jing-Cheng Wang; Xin-Min Feng; Yi-Nan Li; Hai-Xiang Xiao
Journal:  Cytotechnology       Date:  2014-01-01       Impact factor: 2.058

3.  Evaluation of isolation methods and culture conditions for rat bone marrow mesenchymal stem cells.

Authors:  Xueyuan Li; Yang Zhang; Guoxian Qi
Journal:  Cytotechnology       Date:  2012-09-26       Impact factor: 2.058

Review 4.  Stem cells for the cell and molecular therapy of type 1 diabetes mellitus (T1D): the gap between dream and reality.

Authors:  Riccardo Calafiore; Giuseppe Basta
Journal:  Am J Stem Cells       Date:  2015-03-15

5.  Should publications on mesenchymal stem/progenitor cells include in-process data on the preparation of the cells?

Authors:  Roxanne L Reger; Darwin J Prockop
Journal:  Stem Cells Transl Med       Date:  2014-04-01       Impact factor: 6.940

6.  Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs.

Authors:  David R Deyle; Iram F Khan; Gaoying Ren; Pei-Rong Wang; Jordan Kho; Ulrike Schwarze; David W Russell
Journal:  Mol Ther       Date:  2011-10-25       Impact factor: 11.454

7.  Nanotopography as modulator of human mesenchymal stem cell function.

Authors:  Karina Kulangara; Yong Yang; Jennifer Yang; Kam W Leong
Journal:  Biomaterials       Date:  2012-04-18       Impact factor: 12.479

8.  Biological Features of Human Bone Marrow Stromal Cells (hBMSC) Cultured with Animal Protein-Free Medium-Safety and Efficacy of Clinical Use for Neurotransplantation.

Authors:  Hideo Shichinohe; Satoshi Kuroda; Taku Sugiyama; Masaki Ito; Masahito Kawabori; Mitsufumi Nishio; Yukari Takeda; Takao Koike; Kiyohiro Houkin
Journal:  Transl Stroke Res       Date:  2011-06-11       Impact factor: 6.829

9.  ARTEMIS stabilizes the genome and modulates proliferative responses in multipotent mesenchymal cells.

Authors:  Sarah A Maas; Nina M Donghia; Kathleen Tompkins; Oded Foreman; Kevin D Mills
Journal:  BMC Biol       Date:  2010-10-27       Impact factor: 7.431

10.  Adipocyte-derived soluble factor(s) inhibits early stages of B lymphopoiesis.

Authors:  Fareena A Bilwani; Katherine L Knight
Journal:  J Immunol       Date:  2012-09-21       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.